Clinical reversible myelopathy in T-cell lymphoblastic lymphoma treated with nelarabine and radiotherapy: Report of a case and review of literature of an increasing complication

Mediterranean Journal of Hematology and Infectious Diseases

Volumn 7, Issue 1, 2015, Pages

  Tisi, Maria Chiara ^a   Ausoni, Giuseppe ^a   Vita, Maria Gabriella ^a   Tartaglione, Tommaso ^a   Balducci, Mario ^a   Laurenti, Luca ^a   Chiusolo, Patrizia ^a   Hohaus, Stefan ^a   Sica, Simona ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; DEXAMETHASONE; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; MITOXANTRONE; NELARABINE; THYMOCYTE ANTIBODY;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; ATAXIA; BONE MARROW BIOPSY; CANCER RADIOTHERAPY; CASE REPORT; COLITIS; DRUG MEGADOSE; FEMALE; GASTROINTESTINAL SYMPTOM; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN TISSUE; LEUKEMIA REMISSION; LYMPHATIC LEUKEMIA; LYMPHOCYTIC INFILTRATION; MEDIASTINUM MASS; MULTIPLE CYCLE TREATMENT; MYELITIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PARAPLEGIA; PHYSIOTHERAPY; SENSORY DYSFUNCTION; STEM CELL MOBILIZATION; T CELL LYMPHOBLASTIC LEUKEMIA; T LYMPHOCYTE; TUMOR BIOPSY;

EID: 84923677519     PISSN: None     EISSN: 20353006     Source Type: Journal    
DOI: 10.4084/mjhid.2015.025     Document Type: Article

References (14)

1. Cohen MH, Johnson JR, Massie T, Sridhara R, McGuinn WD Jr, Abraham S, Booth BP, Goheer MA, Morse D, Chen XH, Chidambaram N, Kenna L, Gobburu JV, Justice R, Pazdur R. Approval summary: nelarabine for the treatment of T-cell lymphoblastic leukemia/lymphoma. Clin Cancer Res. 2006 Sep 15;12(18):5329-35 http://dx.doi.org/10.1158/1078-0432.CCR-06-0606 PMid:17000665
2. Hoelzer D, Gökbuget N, Digel W, Faak T, Kneba M, Reutzel R, Romejko-Jarosinska J, Zwolinski J, Walewski J. Outcome of adult patients with T-lymphoblastic lymphoma treated according to protocols for acute lymphoblastic leukemia. Blood 2002 ;99:4379-85. http://dx.doi.org/10.1182/blood-2002-01-0110 PMid:12036865
3. Cheson BD. Role of functional imaging in the management of lymphoma. J Clin Oncol 2011 ;29:1844-54. http://dx.doi.org/10.1200/JCO.2010.32.5225 PMid:21482982
4. Common terminology criteria for Adverse Events (CTCAE); v4.03: June 14, 2010. National Institute of Health; National Cancer Institute.
5. Reilly KM, Kisor DF. Profile of nelarabine: use in the treatment of T-cell acute lymphoblastic leukemia. Onco Targets Ther 2009; 2:219-28. PMid:20616909 PMCid:PMC2886323
6. Kurtzberg J, Ernst TJ, Keating MJ, Gandhi V, Hodge JP, Kisor DF, Lager JJ, Stephens C, Levin J, Krenitsky T, Elion G, Mitchell BS. Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies. J Clin Oncol. 2005 May 20;23(15):3396-403. http://dx.doi.org/10.1200/JCO.2005.03.199 PMid:15908652
7. Berg SL, Blaney SM, Devidas M, Lampkin TA, Murgo A, Bernstein M, Billett A, Kurtzberg J, Reaman G, Gaynon P, Whitlock J, Krailo M, Harris MB; Children's Oncology Group. Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group. J Clin Oncol. 2005 May 20;23(15):3376-82. http://dx.doi.org/10.1200/JCO.2005.03.426 PMid:15908649
8. DeAngelo DJ, Yu D, Johnson JL, Coutre SE, Stone RM, Stopeck AT, Gockerman JP, Mitchell BS, Appelbaum FR, Larson RA. Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801. Blood. 2007 Jun 15;109(12):5136-42. http://dx.doi.org/10.1182/blood-2006-11-056754 PMid:17344466 PMCid:PMC1941786
9. Papayannidis C, Iacobucci I, Abbenante MC, Curti A, Paolini S, Parisi S, Baccarani M, Martinelli G. Complete paraplegia after nelarabine treatment in a T-cell acute lymphoblastic leukemia adult patient. Am J Hematol 2010 ;85: 608. http://dx.doi.org/10.1002/ajh.21719 PMid:20658590
10. Forcade E, Leguay T, Vey N, Baruchel A, Delaunay J, Robin M, Socié G, Dombret H, Peffault de Latour R, Raffoux E. Nelarabine for T cell acute lymphoblastic leukemia relapsing after allogeneic hematopoietic stem cell transplantation: an opportunity to improve survival. Biol Blood Marrow Transplant 2013 ;19: 1124-6. http://dx.doi.org/10.1016/j.bbmt.2013.04.010 PMid:23648236
11. Kawakami M, Taniguchi K, Yoshihara S, Ishii S, Kaida K, Ikegame K, Okada M, Watanabe S, Nishina T, Hamada H, Nakagawa M, Ogawa H. Irreversible neurological defects in the lower extremities after haploidentical stem cell transplantation: possible association with nelarabine. Am J Hematol 2013; 88: 853-7. PMid:23757212
12. Gollard RP, Selco S. Irreversible myelopathy associated with nelaribine in T-cell acute lymphoblastic leukemia. J Clin Oncol 2013 ;31:327-31. http://dx.doi.org/10.1200/JCO.2012.45.4728 PMid:23715575
13. Hartz B, Löbel U, Hagel C, Escherich G. Fatal neurological side-effects with necrosis of spinal cord following nelarabine treatment in a child with relapsed T-cell acute lymphoblastic leukemia. Am J Hematol 2013 ;88:1096-7. http://dx.doi.org/10.1002/ajh.23550 PMid:23873785
14. Ngo D, Patel S, Kim EJ, Brar R, Koontz MZ. Nelarabine neurotoxicity with concurrent intrathecal chemotherapy: Case report and review of literature. J Oncol Pharm Practic 2014;0:1-5.